Reply

We thank Drs. Iancu and Ober for their interest in our work (1). We agree that timing of glycoprotein IIb/IIIa inhibitor administration is an important factor. A recent meta-analysis comparing intravenous versus intracoronary abciximab application found a trend toward a greater efficacy with intracoronary abciximab with an ischemic time 
Source: Journal of the American College of Cardiology: Cardiovascular Imaging - Category: Radiology Source Type: research